PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$110.35
as of July 31, 2026 -
YTD RETURNS8.49%
as of July 31, 2026 -
Total Net Assets$925.60M
as of July 31, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 07/31/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
19.21 |
177,849,623 |
|
NVS |
Novartis Ag |
10.50 |
97,167,617 |
|
MRK |
Merck & Co Inc |
9.89 |
91,557,551 |
|
NVO |
Novo Nordisk A/S |
5.23 |
48,365,519 |
|
BMY |
Bristol-Myers Squibb Co |
5.02 |
46,492,752 |
|
PFE |
Pfizer Inc |
4.64 |
42,964,754 |
|
MCK |
Mckesson Corp |
4.63 |
42,870,289 |
|
ABBV |
Abbvie Inc |
4.52 |
41,870,845 |
|
JNJ |
Johnson & Johnson |
4.36 |
40,341,543 |
|
GSK |
Gsk Plc |
4.32 |
39,982,887 |
|
SNY |
Sanofi Sa/France |
4.01 |
37,110,491 |
|
AZN |
Astrazeneca Plc |
3.84 |
35,579,445 |
|
COR |
Cencora Inc |
3.66 |
33,889,048 |
|
HLN |
Haleon Plc |
3.24 |
30,009,301 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
3.13 |
29,002,249 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
3.04 |
28,100,386 |
|
ZTS |
Zoetis Inc |
2.24 |
20,717,043 |
|
VTRS |
Viatris Inc |
1.20 |
11,113,566 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.12 |
10,407,970 |
|
AXSM |
Axsome Therapeutics Inc |
0.68 |
6,274,624 |
|
CORT |
Corcept Therapeutics Inc |
0.66 |
6,090,067 |
|
ELAN |
Elanco Animal Health Inc |
0.38 |
3,473,509 |
|
OGN |
Organon & Co |
0.23 |
2,104,464 |
|
BHC |
Bausch Health Cos Inc |
0.14 |
1,255,592 |
|
PRGO |
Perrigo Co Plc |
0.06 |
536,619 |
|
-EUR CASH- |
-- |
0.00 |
41 |
|
-USD CASH- |
-- |
-0.00 |
-7,815 |
|
-- |
Other/Cash |
0.05 |
479,425 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 06/30/2026
-
Sector
% of Net Assets -
Health Care
99.51 -
Other/Cash
0.49
Country Weightings (%) as at 06/30/2026
-
Country
% of Net Assets -
United States
61.75 -
United Kingdom
11.84 -
Switzerland
10.63 -
Denmark
5.37 -
France
4.00 -
Israel
3.06 -
Japan
2.87 -
Other/Cash
0.49
Fees
Distributions
as of 08/03/2026
Quarterly
1.89%
2.30%
2.00%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency